Stem Cell Therapeutics Announces the Issuance of United States Patent Relating to Prolactin
News Feb 11, 2011
Stem Cell Therapeutics Corp. has announced that it has been granted a patent by the U.S. Patent and Trademark Office -U.S. Patent 7,884,072- entitled, "Prolactin induced increase in neural stem cell number." The claims contained within this issued patent cover methods of using an effective amount of prolactin to increase stem cell numbers in mammals suspected of having neurological diseases.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows: "This issued patent and other anticipated patents for the use of prolactin greatly assist the protection and capture of shareholder value for this therapeutic program. The important exclusivity that has been granted for the use of prolactin today combined with ever increasing scientific evidence supporting the use of prolactin builds upon the wealth of intellectual property that SCT possesses. We look forward to the continued advancement of this program in the future."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019